CircRNAs derived from the tyrosine phosphatase PTPN22 impact chemosensitivity in ALK-positive T-cell lymphomas
A circular RNA linked to early relapse in aggressive lymphoma works through a specific pathway, suggesting CARM1 inhibition might overcome drug resistance.
RNA-Seq of primary ALK+ ALCL biopsies identified circPTPN22 as upregulated in early relapse, working via the ALK/STAT3 pathway to suppress CARM1 and promote drug tolerance. CARM1 inhibition emerges as a potential strategy to overcome chemoresistance in this aggressive lymphoma subtype.
What the study was
- Study design
- Translational study — RNA-Seq of primary biopsies + functional in vitro validation
- Population
- Primary ALK+ ALCL biopsies (relapsed vs non-relapsed); Jurkat/ALK+ lymphoma cell lines
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Sci Rep
Why it surfaced
Novel circRNA-CARM1 axis in ALK+ ALCL chemoresistance; CARM1 is a druggable target. Primary biopsy data strengthens translational relevance. In vitro validation limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.